Join our daily newsletter At The Bell to receive exclusive market insights
- Advanced Human Imaging (AHI) has been granted medical device approval for DermaScan AI across all 27 countries in the European Union
- The ASX-lister received European Conformity approval for its DermaScan AI engine — which has been developed and patented by AHI’s partner Triage
- The European Conformity approval means Derma AI, which hosts the ability to identify 588 skin conditions in 133 categories including cancers, can now be used in over 200 countries, according to AHI
- Further to this, DermaScan is also set to be embedded into AHI’s CompleteScan health management app later this year
- Advanced Human Imaging shares are off 0.67 per cent and trading at $1.48
Advanced Human Imaging (AHI) has been granted medical device approval for DermaScan AI across all 27 countries in the European Union.
The DermaScan AI engine — which has been developed and patented by AHI’s partner Triage — can identify 588 skin conditions in 133 categories and is reported to identify all categories of skin cancers.
According to AHI, the European Conformity approval means Derma AI can now be used in over 200 countries, allowing the technology to detect and identify skin conditions across all skin types.
Further to this, DermaScan is also set to be embedded into AHI’s CompleteScan health management app later this year.
Broadly, the ASX-lister said receiving CE Mark approval marks a substantive milestone for the company and its partnership with Triage, with FDA approval for the U.S. expected in the second half of this year.
In addition, Triage has signed a distribution agreement with SkinHealth Canada group to supply 2000 professionals in Canada with these DermaScan AI capabilities.
Advanced Human Imaging’s Chief Executive Officer Vlado Bosanac said the approval opens up the market significantly for AHI and Triage.
“On the back of Google announcing their entry into the world of AI-driven dermatology last week, I am elated with the granting of the CE medical device approval for the Derma AI,” he commented.
Advanced Human Imaging shares are off 0.67 per cent and trading at $1.48 at 11:06 am AEST.
